Point72 Asset Management
KZR

Point72 Asset Management’s Kezar Life Sciences KZR Stock Holding History

Point72 Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-56
Closed -$1.38K – 2693
2023
Q2 		$1.38K Sell
56
-3,784
-99% -$98.5K ﹤0.01% 1991
2023
Q1 		$120K Buy
+3,840
New +$222K ﹤0.01% 1597
2022
Q3 		– Sell
-160,840
Closed -$13.3M – 1578
2022
Q2 		$13.3M Sell
160,840
-65,689
-29% -$5.79M 0.06% 432
2022
Q1 		$37.6M Buy
226,529
+15,980
+8% +$2.29M 0.15% 192
2021
Q4 		$35.2M Buy
+210,549
New +$23.8M 0.14% 201
2019
Q2 		– Sell
-20,600
Closed -$3.65M – 1444
2019
Q1 		$3.65M Buy
20,600
+8,100
+65% +$1.6M 0.02% 620
2018
Q4 		$2.95M Buy
+12,500
New +$3.05M 0.01% 661

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's KZR Position: Q3 2023 in Review

Point72 Asset Management sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 56 shares — an estimated $1.38K sold.

Point72 Asset Management first reported a position in KZR in Q4 2018 and held it in 7 quarters. The position peaked at $37.6M in Q1 2022. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

  • Point72 Asset Management reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
  • Point72 Asset Management sold 56 Kezar Life Sciences shares in Q3 2023, an estimated $1.38K.
  • Point72 Asset Management first reported a position in Kezar Life Sciences in Q4 2018 and held it in 7 quarters.
  • Point72 Asset Management's Kezar Life Sciences position peaked at $37.6M in Q1 2022.
  • 82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.